Response Letter to "Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China"

被引：0
|
作者：
Guan, Haijing [1 ]
Sheng, Yanan [2 ]
Guo, Wanjie [3 ]
Han, Sheng [3 ]
Shi, Luwen [1 ]
机构：
[1] Peking Univ, Sch Pharmaceut Sci, Beijing, Peoples R China
[2] Peking Univ, China Ctr Hlth Econ Res, Beijing, Peoples R China
[3] Peking Univ, Int Res Ctr Med Adm, Beijing, Peoples R China
来源：
ADVANCES IN THERAPY | 2020年 / 37卷 / 02期
关键词：
Alectinib; ALK; China; Cost-Effectiveness; NSCLC; CRIZOTINIB;
D O I：
10.1007/s12325-019-01202-2
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：971 / 972
页数：2
相关论文
共 50 条
  • [21] Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer
    Wu, Yi-Long
    Dziadziuszko, Rafal
    Ahn, Jin Seok
    Barlesi, Fabrice
    Nishio, Makoto
    Lee, Dae Ho
    Lee, Jong-Seok
    Zhong, Wenzhao
    Horinouchi, Hidehito
    Mao, Weimin
    Hochmair, Maximilian
    de Marinis, Filippo
    Migliorino, M. Rita
    Bondarenko, Igor
    Lu, Shun
    Wang, Qun
    Ochi Lohmann, Tania
    Xu, Tingting
    Cardona, Andres
    Ruf, Thorsten
    Noe, Johannes
    Solomon, Benjamin J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (14): : 1265 - 1276
  • [22] Alectinib for treatment of ALK-positive non-small-cell lung cancer
    Avrillon, Virginie
    Perol, Maurice
    FUTURE ONCOLOGY, 2017, 13 (04) : 321 - 335
  • [23] Alectinib for advanced ALK-positive non-small-cell lung cancer
    Ly, Ashley C.
    Olin, Jacqueline L.
    Smith, Morgan B.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2018, 75 (08) : 515 - 522
  • [24] Pharmacoeconomic Analysis of Brigatinib Versus Alectinib in Chinese Patients with ALK-Positive Non-Small Cell Lung Cancer
    Chai, Q.
    Gu, C.
    Zhang, Y. -J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S738 - S738
  • [25] The cost-effectiveness of brigatinib in adult patients with ALK inhibitor-naive ALK-positive non-small cell lung cancer from a US perspective
    Cranmer, Holly
    Kearns, Isabella
    Young, Melanie
    Humphries, Michael J.
    Trueman, David
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2022, 28 (09): : 970 - 979
  • [26] Alectinib in a patient with ALK-positive non-small lung cancer unable to swallow capsules
    Ishiura, Yoshihisa
    Nomura, Shosaku
    Ishii, Yuka
    Imai, Kai
    Nakahama, Kahori
    Sawai, Yusuke
    Tamaki, Takeshi
    Shimizu, Toshiki
    Miyashita, Naoyuki
    Ito, Tomoki
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (05) : 1283 - 1285
  • [27] Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
    Morcos, Peter N.
    Nueesch, Eveline
    Jaminion, Felix
    Guerini, Elena
    Hsu, Joy C.
    Bordogna, Walter
    Balas, Bogdana
    Mercier, Francois
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (01) : 129 - 138
  • [28] Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer
    Burudpakdee, C.
    Wong, W.
    Seetasith, A.
    Corvino, F. A.
    Yeh, W.
    Gubens, M.
    LUNG CANCER, 2018, 119 : 103 - 111
  • [29] Alectinib/crizotinibDevelopment of drug resistance in ALK-positive non-small cell lung cancer: case report
    Reactions Weekly, 2020, 1829 (1) : 23 - 23
  • [30] Bayesian analysis supports the role of alectinib and ensartinib for ALK-positive non-small cell lung cancer
    Rizzo, Alessandro
    THORACIC CANCER, 2023, 14 (13) : 1217 - 1217
12345